A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of PF-06940434 in Patients with Advanced or Metastatic Solid Tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
March 17, 2021
End Date
September 6, 2024
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
March 17, 2021
End Date
September 6, 2024